Dose-Response of Salmeterol in Children

Completed · Phase 4

Conditions studied: Asthma

In brief

To examine whether a breathing test (methacholine challenge using impulse oscillometry) can be used to tell the difference between two different doses of an inhaled drug, salmeterol, delivered by Advair in children with asthma

Key facts

Study ID

NCT01907334

Run by

University of Florida

People needed

10

Starts

2013-08-01

Expected to finish

2014-07-01

Last updated by the study team

2014-10-07

Who can join

Age: 4 and older, up to 11. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• parent/legal guardian and subject must be able to speak and understand English and patient must be willing and able to give assent to take part in the study
• diagnosed with asthma for at least 6 months
• able to demonstrate inhalation technique with study device
• if taking inhaled corticosteroids, dose must be stable for 2 weeks
• no significant concomitant medical conditions or abnormal physical findings on screening except for those consistent with asthma and allergic rhinitis
• airway responsiveness to methacholine with a baseline provocational dose causing an increase of at least 40% in R5 (PC40R5) at no more than 8 mg/mL

You may not qualify if…

• female who has started menstruating
• past or present history of any allergic reaction to any of the medications or formulations administered in this study
• prior treatment with systemic corticosteroids in last 30 days or more than 4 courses in previous 12 months
• use of short-acting beta-agonist more than two times per week in the previous month
• use of long-acting beta-agonist in the 3 weeks before the first methacholine challenge or during the study
• change in dosage of inhaled corticosteroids in previous 30 days, nasal steroids in previous 15 days and montelukast in last 7 days
• history of life-threatening asthma, including loss of consciousness, intubation and/or admission to ICU
• hospitalization for acute asthma within past year
• inability to withhold the following medications before methacholine challenges:
• short-acting beta-agonists at least 6 hours
• regular long-acting beta-agonists at least 3 weeks
• inhaled corticosteroid at least 2 hours
• montelukast at least 24 hours
• aspirin and non-steroid anti-inflammatory drugs at least 48 hours
• caffeine at least 4 hours

Where it is running

• University of Florida Asthma Research Lab — Gainesville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.